Navigation Links
Januvia Pancreatic Cancer Lawsuit: Bernstein Liebhard LLP Comments on Growing Litigation Surrounding Januvia

New York, New York (PRWEB) July 14, 2013

Januvia pancreatic cancer lawsuit claims, as well as complaints alleging the drug caused patients to develop pancreatitis and thyroid cancer, continue to mount in courts throughout the U.S. According to court records, the U.S. Judicial Panel on Multidistrict Litigation (JPML) is currently considering a proposal to consolidate all federal Januvia lawsuits, as well as claims involving similar diabetes drugs in the same incretin mimetics class, in a single federal court for pretrial proceedings. On April 29th, 2013, Merck & Co., the maker of Januvia, voiced support for the establishment of a multidistrict litigation for all federal claims involving the drug. However, the company is seeking to have the litigation limited to allegations that use of incretin mimetics, including Januvia, caused pancreatic cancer. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)

“We agree that the establishment of a consolidated litigation would allow claims involving incretin mimetics, including Januvia lawsuits, to proceed efficiently, ” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Januvia lawsuit consultations to victims of pancreatic cancer, pancreatitis and thyroid cancer that may be associated with the drug.

Januvia and Pancreatic Cancer

Januvia, which mimics the action of hormones in the intestinal tract that stimulate the pancreas to produce insulin, was brought to market in 2006. In 2009, a caution regarding a potential link between Januvia and pancreatitis was added to the drug’s label after the U.S. Food & Drug Administration (FDA) became aware of 88 post-marketing cases of acute pancreatitis in patients taking the drug.* Januvia also appeared to increase the risk of pancreatic cancer and pancreatitis in a study published in 2011 in Gastroenterology. Two cases of thyroid cancer were also reported in the patients who took Januvia. **

In March 2013, the FDA said it had begun investigating incretin mimetics, including Januvia, after results from an unpublished study indicated these medications might cause pre-cancerous changes in the pancreas. Most recently, a report published June 10th in the British Medical Journal revealed previously unpublished data that indicated the manufacturers of incretin mimetics may have downplayed the drugs’ potential to harm the pancreas.***

Court records indicate that more than 50 product liability claims involving incretin mimetics, including Januvia pancreatic cancer lawsuits, have been filed in federal courts around the country. The JPML will hear Oral Arguments on the possible consolidation of those claims on July 25th.

Patients who have developed pancreatic cancer, thyroid cancer or pancreatitis allegedly due to Januvia may be entitled to compensation for medical bills, lost wages, pain and suffering and more. To learn more about filing a Januvia lawsuit, please visit Bernstein Liebhard LLP’s website. For more information, please call 800-511-5092.

* 25, 2009
**, Gastroenterology, February 21, 2011
***; BMJ, June 10, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:

Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Federal Byetta, Victoza, Januvia Lawsuits Could See Consolidation This Month, Rottenstein Law Group LLP Reports
2. Rottenstein Law Group LLP Acknowledges BMJ Study of Risks of Byetta, Januvia
3. New analysis shows that patients with Type 2 diabetes and mild renal impairment had similar improvement in blood sugar control and experienced less hypoglycemia with JANUVIA (sitagliptin) compared to sulfonylurea
4. DrugRisk Update: Panel To Decide Fate of Januvia Lawsuits Next Week
5. Januvia Pancreatic Cancer Lawsuits: Bernstein Liebhard LLP Comments on Medical Journal’s Investigation of Incretin Mimetics
6. Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics
7. Rottenstein Law Group LLP Comments on Drugmakers’ Cooperation With Safety Review of Byetta, Januvia, Victoza
8. Januvia Lawsuit News: Rottenstein Law Group LLP Comments on Doctor’s Doubts About Januvia
9. Januvia Lawsuits Consultations Now Offered by the Berman Law Group, Januvia Lawyers and Compensation Experts
10. DrugRisk Adds New Pancreatic Cancer Warning for Diabetes Drug Januvia
11. Pancreatic Cancer Correlation to Type 2 Diabetes Drugs Januvia and Byetta, New Studies Find Possible Connection
Post Your Comments:
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... substance abuse located in central Michigan, have come together on Thanksgiving Day to ... produced video, available for viewing on the Serenity Point YouTube channel, patients displayed ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied ... the need to integrate dose form selection in early phase drug development. The ... organization supporting and bringing together the UK’s emerging life sciences companies, corporate partners, ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer ... classically-influenced trailer titles work with any font, giving users limitless opportunities to stylize ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... accessible for all, Water For Empowerment ™ attracts volunteers together who want ... water by empowering women as key stakeholders in the process. The non-profit launched ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... factory direct sauna parts and accessories. , Sauna accessories help improve the bather ... style and personality. From basic styles for the purist looking for simplicity in ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Nov. 25, 2015 On Tuesday, November ... bellwether trial against Wright Medical Technology, Inc. for ... Conserve metal-on-metal hip implant device, awarded $11 million ... two week trial and three days of deliberations, ... device was defectively designed and unreasonably dangerous, and ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan plc (NYSE: ... agreement with the New York State ... of the Sherman Act, and other statutes with the Attorney ... February 2014, to cease marketing and selling the now generic ... settlement, Allergan admits no liability, has released its counterclaims against ...
(Date:11/25/2015)... Endo International plc (NASDAQ: ENDP ) (TSX: ENL) today ... will discuss corporate updates at the 27 th Annual ... on Wednesday, December 2, 2015 at 1 p.m. ET. ... then the link to the event. Participants should allow approximately ... the site and download any streaming media software needed to ...
Breaking Medicine Technology: